Clinical Trial Update: Efficacy and Safety of KI1001 in the Treatment of ≥ 55 Years Old Insomnia Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating KI1001 for insomnia in adults age 55 and older has completed, with an update on efficacy and safety findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• KI1001

Snippet

Sponsor: Kuhnil Pharmaceutical Co., Ltd. | Conditions: Sleep Initiation and Maintenance Disorders | Phase 3 | Status: COMPLETED